SEARCH

SEARCH BY CITATION

References

  • 1
    Standl E, Schnell O. A new look at the heart in diabetes mellitus: from ailing to failing. Diabetologia 2000; 43: 144569.
  • 2
    Ryden L, Standl E, Bartnik M, et al. Guidelines on diabetes, pre-diabetes, and cardiovascular diseases: executive summary. The task Force on diabetes and cardiovascular diseases of the European Society of Cardiology (ESC) and of the European Association for the Study of Diabetes (EASD). Eur Heart J 2007; 28: 88136.
  • 3
    Juutilainen A, Lehto S, Ronnemaa T, Pyorala K, Laakso M. Similarity of the impact of type 1 and type 2 diabetes on cardiovascular mortality in middle-aged subjects. Diabetes Care 2008; 31: 7149.
  • 4
    Jansson SPO, Andersson DKG, Svärdsudd K. Mortality trends in subjects with and without diabetes during 33 years of follow-up. Diabetes Care 2010; 33: 55156.
  • 5
    International Diabetes Federation. Diabetes atlas. http://www idf org/diabetesatlas 2009 Accessed 16 August 2011.
  • 6
    Elliot WJ, Meyer PM. Incident diabetes in clinical trials of antihypertensive drugs: a network meta-analysis. Lancet 2007; 369: 2017.
  • 7
    Standl E. Effects of hydrochlorothiazide on the serum insulin concentrations of dogs after intravenous glucose tolerance test. Doctor’s thesis (inaugural dissertation) 1967.
  • 8
    Staessen JA, Wang JG, Thijs L. Cardiovascular prevention and blood pressure reduction: a quantitative overview updated until 1 March 2003. J Hypertension 2003; 21: 105576.
  • 9
    Law MR, Morris JK, Wald NJ. Use of blood pressure lowering drugs in the prevention of cardiovascular disease: meta-analysis of 147 randomized trials in the context of expectations from prospective epidemiological studies. Brit Med J 2009; 338: b1665.
  • 10
    Wiysonge CS, Bradley H, Mayosi BM, et al. Beta-blockers for hypertension. Cochrane Database Syst Rev 2007 Jan 24: CD 002003.
  • 11
    Chen JM, Heran BS, Perez MI, Wright JM. Blood pressure lowering efficacy of beta-blockers as second-line therapy for primary hypertension. Cochrane Database Syst Rev 2010 Jan 20: CD 007185.
  • 12
    The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 2002; 288: 97.
  • 13
    Kostis JB, Wilson AC, Freudenberger RS, Cosgrove NM, Pressel SL, Davis BR. Long-term effect of diuretic-based therapy on fatal outcomes in subjects with isolated systolic hypertension with and without diabetes. Am J Cardiol 2005; 95: 2935.
  • 14
    Verdecchia P, Reboldi G, Angeli F, et al. Adverse prognostic significance of new diabetes in treated hypertensive subjects. Hypertension 2004; 43: 9639.
  • 15
    Bakris G, Molitch M, Hewkin A, et al. Differences in glucose tolerance between fixed-dose antihypertensive drug combinations in people with metabolic syndrome. Diabetes Care 2006; 29: 25927.
  • 16
    Chrysant SG. Commentary: the ALLHAT study: results and clinical implications. QJ MED 2003; 96: 7713.
  • 17
    Kostis JB, Cabrera J, Cheng JQ, et al. Association between chlorthalidone treatment of systolic hypertension and long-term survival. JAMA 2011; 306: 258893.
  • 18
    Fonseca VA. Effects of beta-blockers on glucose and lipid metabolism. Curr Med Res Opin 2010; 26: 61529.
  • 19
    The Navigator Study Group. Effect of valsartan on the incidence of diabetes and cardiovascular events. N Engl J Med 2010; Published online on Accessed 14 March Doi: 10.1056/NEJMoa1001121.
  • 20
    The DREAM Trial Investigators. Effect of ramipril on the incidence of diabetes. N Engl J Med 2006; 355: 155162.
  • 21
    Diabetes Prevention Program Research Group. Reduction in the incidence of type 2 diabetes with life style intervention or metformin. N Engl J Med 2002; 346: 93403.
  • 22
    Chiasson JL, Josse RG, Gomis R. Acarbose for prevention of type 2 diabetes mellitus: the STOP-NIDDM randomised trial. Lancet 2002; 359: 20727.
  • 23
    DREAM Investigators. Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomized controlled trial. Lancet 2006; Doi: 10.1016/S0140-6736(06)69420-8.
  • 24
    DeFronzo RA, Tripathy D, Schwenke DC, et al. Pioglitazone for diabetes prevention in impaired glucose tolerance. N Engl J Med 2011; 364: 110415.
  • 25
    UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998; 352: 83753.
  • 26
    The Diabetes Control, Complication Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of longterm complications of insulin-dependent diabetes mellitus. N Engl J Med 1993; 329: 997896.
  • 27
    Ray KK, Seshasai SR, Wijesuriya S, et al. Effect of intensive control of glucose on cardiovascular outcomes and death in patients with diabetes mellitus: a meta-analysis of randomised controlled trials. Lancet 2009; 373: 176572.
  • 28
    Turnbull FM, Abraira C, Anderson RJ, et al. Intensive glucose control and macrovascular outcomes in type 2 diabetes. Diabetologia 2009; 52: 228898.
  • 29
    The epidemiology of diabetes interventions and complications (EDIC) study. Sustained effect of intensive treatment of type 1 diabetes mellitus on development and progression of diabetic nephropathy. JAMA 2003; 290: 215967.
  • 30
    Holman RR, Sanjoy KP, Bethel A, Matthews DR, Neil HAW. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med 2008; 359: 157789.
  • 31
    Gaede P, Vedel P, Larsen N, Jensen GV, Parving HH, Pedersen O. Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J Med 2003; 348: 38393.
  • 32
    Gaede P, Lund-Andersen H, Parving HH, Pedersen O. Effect of multifactorial intervention on mortality in type 2 diabetes. N Engl J Med 2008; 358: 58091.
  • 33
    Hypertension in Diabetes Study. III. Prospective study of therapy of hypertension in type 2 diabetic patients: efficacy of ACE inhibitor and beta-blockade. Diabetic Med 1994; 11: 77382.
  • 34
    Hypertension in Diabetes Study Group. Hypertension in Diabetes Study IV. Therapeutic requirements to maintain tight blood pressure control. Diabetologia 1996; 39: 155461.
  • 35
    UK Prospective Diabetes Study Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. Brit Med J 1998; 317: 70313.
  • 36
    UK Prospective Diabetes Study Group. Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 39. Brit Med J 1998; 31720.
  • 37
    Holman RR, Sanjoy KP, Bethel MA, Neil HAW, Matthews DR. Long-term follow-up after tight control of blood pressure in type 2 diabetes. N Engl J Med 2008; 156576.
  • 38
    Patel A, MacMahon S, Chalmers J, et al. Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomized controlled trial. Lancet 2007; 370: 82940.
  • 39
    Holman RR, Paul S, Farmer A, et al. Atorvastatin in factorial with omega-3 EE90 risk reduction in diabetes (AFORRD): a randomized controlled trial. Diabetologia 2009; 52: 509.
  • 40
    Yamaji M, Tsutamoto T, Kawahara C, et al. Effects of eplerenone versus spironolactone on cortisol and haemoglobin A1c levels in patients with chronic heart failure. Am Heart J 2010; 160: 91521.
  • 41
    Jamerson K, Bakris GL, Dahlöf B, Pitt B, Velazquez EJ, Weber MA for the ACCOMPLISH Investigators. Avoiding Cardiovascular Events through COMbination therapy in Patients LIving with Systolic Hypertension (The ACCOMPLISH Study). N Engl J Med 2008; 359: 241728.
  • 42
    Weber MA, Bakris GL, Jamerson K, et al. Cardiovascular events during differing hypertension therapies in patients with diabetes. Am Coll Cardiol 2010; 56: 7785.
  • 43
    Turnbull F, et al. Effects of different regimens to lower blood pressure on major cardiovascular events in older and younger adults: meta-analysis of randomized trials. Brit Med J 2008; 336: 112123.
  • 44
    Wright JM, Musini VM. First-line drugs for hypertension. Cochrane Database Syst Rev 2009 Jul 8: CD001841.
  • 45
    Chen N, Zhou M, Yang M, et al. Calcium channel blockers versus other classes of drugs for hypertension. Cochrane Database Syst Rev 2010; 4: CD–003658.
  • 46
    Klingbeil AU, Schneider M, Martus P, Messerli FH, Schmieder RE. A meta-analysis of the effects of treatment on left ventricular mass in essential hypertension. Am J Med 2003; 115: 416.
  • 47
    Conlin PR, Gerth WC, Fox J, Roehm JB, Boccuzzi SJ. Four-year persistence patterns among patients initiating therapy with the angiotensin II receptor antagonist losartan versus other antihypertensive drug classes. Clin Therapeutics 2001; 23: 19992010.